[1]刘清权,查金顺,王耀国,等.甲状腺功能与冠脉病变程度的相关性研究[J].国际放射医学核医学杂志,2013,37(6):340-344.[doi:10.3760/cma.j.issn.1673-4114.2013.06.004]
　LIU Qing-quan,ZHA Jin-shun,WANG Yao-guo,et al.Correlation between thyroid function and the severity of coronary artery disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):340-344.[doi:10.3760/cma.j.issn.1673-4114.2013.06.004]
点击复制

甲状腺功能与冠脉病变程度的相关性研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第6期
页码:
340-344
栏目:
论著
出版日期:
2013-11-25

文章信息/Info

Title:
Correlation between thyroid function and the severity of coronary artery disease
作者:
刘清权1;  查金顺2;  王耀国1;  杜心清1
1. 福建医科大学附属第二医院心内科, 泉州 362000;
2. 福建医科大学附属第二医院核医学科, 泉州 362000
Author(s):
LIU Qing-quan1;  ZHA Jin-shun2;  WANG Yao-guo1;  DU Xin-qing1
Department of Cardiology, the Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China
关键词:
甲状腺激素类; 冠心病; Gensini评分
Keywords:
Thyroid hormones; Coronary artery disease; Gensini scoring
DOI:
10.3760/cma.j.issn.1673-4114.2013.06.004
摘要:
目的 探讨甲状腺激素水平与冠心病及其严重性的关系.方法 冠心病患者158例,根据选择性冠状动脉造影证实冠脉病变狭窄程度,将其分为冠脉狭窄组60例和冠脉无狭窄组(对照组)98例,再将冠脉狭窄组按狭窄累及范围分为单支病变组30例、双支病变组15例和多支(3支以上)病变组15例.采用电化学发光法检测游离三碘甲腺原氨酸(fT3)、游离甲状腺素(fT4)和促甲状腺激素(TSH)水平;采用胆固醇氧化酶法测定高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)等指标.采用Gensini评分来评价受试者冠脉狭窄程度.结果 与对照组比较,冠脉狭窄的双支病变组和多支病变组患者fT3水平显著降低(t=1.947、6.415,P均<0.05),冠脉狭窄单支病变组fT4水平显著升高(t=3.026,P<0.05).采用Logistic回归分析发现,fT3是冠心病的独立危险因素.以Gensini评分为因变量进行多元线性回归分析发现,fT3与Gensini评分呈负相关,fT3每降低0.234 pmol/L,Gensini评分升高1分.结论 fT3水平在冠状动脉狭窄患者中显著降低,并且与冠心病的严重程度密切相关,是冠心病的独立危险因素;fT3每降低0.234 pmol/L,Gensini评分升高1分,可以作为冠心病风险增加的敏感指标.
Abstract:
Objective To explore the correlation between thyroxine hormone and the severity of coronary artery disease (CAD).Methods 158 patients with coronary adisease were entered consecutively into the study.They were separated into control group (absence of CAD,n=98) and CAD group (presence of CAD,n=60).Based on the number of vessel disease,CAD group was further divided into three sub-groups:single-vessel CAD subgroup (n=30),bi-vessel CAD subgroup (n=15) and multi-vessel CAD subgroup (n=15).Serum free triiodothyronine (fT3),free thyroxine (fT4),thyroid stimulating hormone (TSH) were tested by electrochemiluminescence; high density lipoprotein cholesterol (HDL-C) and total cholesterol (TC) were measured by cholesterol oxidase method; and Gensini scoring system was used to evaluate the degree of coronary artery stenosis.Results The levels of fT3 in both bi-vessel CAD and multi-vessel subgroups were higher than those in control group (t=1.947,6.415,both P<0.05).And the level of fT4 in multi-vessel subgroup was also higher than that in control group (t=3.026,P<0.05).fT3 was an independent risk factor of CAD using Logistic regression model.In addition,fT3 was negatively correlated with Gensini scoring inmultiple linear regressions.Gensini scores would increase by 1 as long as the level oft fT3 decreases 0.234 pmol/L.Conclusions fT3 level decreased in patients with CAD,and correlated with the severity of CAD.Gensiniscores would increase 1 as long as fT3 decreases 0.234 pmol/L,which could be supposed as a sensitive predictor of CAD.

参考文献/References:

[1] Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med, 2001, 344(7):501-509.
[2] Duntas LH. Thyroid disease and lipids. Thyroid, 2002, 12(4):287-293.
[3] Biondi B, Klein I. Hypothyroidi sm as a risk factor for cardiovascu-lar disease. Endocrine, 2004, 24(1):1-13.
[4] Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 1983, 51(3):606.
[5] Miura S, Iitaka M, Suzuki S, et al. Decrease in serum levels of thyroid hormone in patients with coronary heart disease. Endocr J, 1996,43(6):657-663.
[6] Muller B, Tsakiris DA, Roth CB, et al. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. EurJ Clin Invest, 2001, 31(2):131-137.
[7] Pretnar-Oblak J, Sebestjen M, Sabovic M. Statin treatment improves cerebral more than systemic endothelial dysfunction in patients with arterial hypertension. Am J Hypertens, 2008, 21(6):674678.
[8] De Pergola G, Ciampolillo A, Paolotti S, et al. Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance,metabolic parameters and blood pressure in overweight and obese women. Clin Endocrinol(Oxf), 2007, 67(2):265-269.
[9] Knudsen N, Laurberg P, Rasmussen LB, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab, 2005,90(7):4019-4024.
[10] Iqbal A, Figenschau Y, Jorde R. Blood pressure in relation to serum thyrotropin:the Tromso study. J Hum Hypertens, 2006, 20(12):932-936.
[11] Park HT, Cho GJ, Ahn KH, et al. Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women. Maturitas, 2009, 62(3):301-305.
[12] Asvold BO, Vatten LJ, Nilsen TI, et al. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol, 2007, 156(2):181-186.
[13] Dullaart RP, de Vries R, Roozendaal C, et al. Carotid artery intima media thickness is inversely related to serum free thyroxine in euthyroid subjects. Clin EndocrinolfOxf), 2007, 67(5):668-673.
[14] Roos A, Bakker SJ, Links TP, et al. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab, 2007, 92(2):491-496.
[15] Tatar E, Kircelli F, Asci G, et al. Associations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Clin J Am Soc Nephrol, 2011,6(9):2240-2246.
[16] Coceani M, Iervasi G, Pingitore A, et al. Thyroid hormone and coronary artery disease:from clinical correlations to prognostic implications. Clin Cardiol, 2009, 32(7):380-385.
[17] 陈志奎,胡申江,刘春霞,等.冠心病患者的血清甲状腺激素水平.中国内分泌代谢杂志,2004, 20(2):143-144.
[18] Pingitore A, Landi P, Taddei MC, et al. Triiodothyronine levels for risk stratification of patients with chronic heart failure.Am J Med, 2005,118(2):132-136.
[19] Iervasi G, Landi P, Raciti M, et al. Low-T3 syndrome:a strong prognostic predictor of death in patients with heart disease. Circulation, 2003, 107(5):708-713.
[20] Ertas F, Kaya H, Soydinc MS. Low serum free triiodothyronine levels are associated with the presence and severity of coronary artery disease in the euthyroid patients:an observational study. Anadolu Kardiyol Derg, 2012, 12(7):591-596.

相似文献/References:

[1]贾超翼,乔立,史嘉琪,等.甲状腺激素治疗亚临床甲状腺功能减退症对血脂水平影响的荟萃分析[J].国际放射医学核医学杂志,2016,40(5):350.[doi:10.3760/cma.j.issn.1673-4114.2016.05.005]
　Jia Chaoyi,Qiao Li,Shi Jiaqi,et al.Effect of L-thyroxine versus placebo treatment on serum lipid levels in subclinical hypothyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):350.[doi:10.3760/cma.j.issn.1673-4114.2016.05.005]
[2]陈宁琳,鲍逸民,杨永青.血浆ATⅡ、NPY、IGF-1和hs-CRP水平测定在评估冠心病患者严重程度中的应用价值[J].国际放射医学核医学杂志,2014,38(3):167.[doi:10.3760/cma.j.issn.1673-4114.2014.03.007]
　Chen Ninglin,Bao Yimin,Yang Yongqing.The application value of plsama ATⅡ, NPY, IGF-1 and hs-CRP levels in evaluation of coronary heart disease severity[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):167.[doi:10.3760/cma.j.issn.1673-4114.2014.03.007]
[3]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
　ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[4]薛倩倩,姚稚明.冠状动脉钙化积分、心肌灌注显像及其联合应用的临床价值[J].国际放射医学核医学杂志,2013,37(5):301.[doi:10.3760/cma.j.issn.1673-4114.2013.05.012]
　XUE Qian-qian,YAO Zhi-ming.The clinic application of coronary artery calcification scores and myocardial perfusion imaging and the combination[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):301.[doi:10.3760/cma.j.issn.1673-4114.2013.05.012]
[5]吴卫元,杨永青.甲状腺激素在心血管疾病诊断和治疗中的临床应用[J].国际放射医学核医学杂志,2010,34(4):223.[doi:10.3760/cma.j.issn.1673-4114.2010.04.009]
　WU Wei-yuan,YANG Yong-qing.Clinical application of thyroid hormone in diagnosis and therapy on cardiovascular disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):223.[doi:10.3760/cma.j.issn.1673-4114.2010.04.009]
[6]苏应瑞,查金顺,许朝祥,等.阻塞性睡眠呼吸暂停低通气综合征伴冠心病:血清高半胱氨酸和C-反应蛋白水平及临床意义[J].国际放射医学核医学杂志,2011,35(5):275.[doi:10.3760/cma.j.issn.1673-4114.2011.05.005]
　SU Ying-rui,ZHA Jin-shun,XU Chao-xiang,et al.Evaluation and clinical significance of serum C-reactive protein and homocysteine level in obstructive sleep apnea/hypopnea syndrome complicated with coronary heart disease patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):275.[doi:10.3760/cma.j.issn.1673-4114.2011.05.005]
[7]崔丽群,杨宝军.甲亢患者尿β2-微球蛋白、白蛋白、免疫球蛋白G联检及临床分析[J].国际放射医学核医学杂志,2009,33(6):356.[doi:10.3760/cma.j.issn.1673-4114.2009.06.012]
　GUI Li-qun,YANG Bao-jun.Joint detection and clinical analyse of urine β2-microglobulin,albumin and immunoglobulin G in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):356.[doi:10.3760/cma.j.issn.1673-4114.2009.06.012]
[8]张志祥,郑岚,罗加,等.131I治疗Graves病伴白细胞减少的临床研究[J].国际放射医学核医学杂志,2008,32(4):230.
　ZHANG Zhi-xiang,ZHENG Lan,LUO Jia,et al.Clinical study on 131I therapy Graves disease complicated with peripheral blood leukcytopenia[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(6):230.
[9]林琛,王鲁华,李俊雄,等.131Ⅰ治疗Graves’甲状腺亢进症伴白细胞减少前后血清和尿中β2-微球蛋白变化分析[J].国际放射医学核医学杂志,2007,31(2):98.
　LIN Chen,WANG Lu-hua,LI Jun-xiong,et al.Changes of serum and urine β2-microglobulin of leukopenia in hyperthyroidism of Graves’ disease before and after 131Ⅰ therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):98.
[10]杨斌,李殿富.存活心肌判断中存在的问题及其原因[J].国际放射医学核医学杂志,2006,30(1):21.
　YANG Bin,LI Dian-fu.The problems and the causes in viable myocardial detection[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):21.

备注/Memo

备注/Memo:
收稿日期:2013-09-11。
通讯作者:査金顺,Email:zjs630805@126.com
更新日期/Last Update: 1900-01-01